Company

Aarhus University Hospital

Source-reviewedGoverned LongevityNext intelligence profile

Evidence reviewed through2026-08-07

Executive intelligence snapshot

Current reviewed view

A reviewed company profile connected to Nicotinamide riboside and Nicotinamide riboside in obese insulin-resistant men in the current LongevityNext intelligence graph.

This profile includes 2 reviewed relationship(s) and 2 reviewed source(s).

This view is bounded by reviewed evidence and does not provide a recommendation or a claim beyond the stated review date.

Evidence state

Source-reviewed

Evidence reviewed through2026-08-07

Evidence state

What the evidence supports

Aarhus University Hospital

Evidence boundary

Key limitations

Interpretation remains bounded to this reviewed profile and does not support broader inference.
Does not establish efficacy, mechanism falsification, approval, utility, rejuvenation, or investment attractiveness.

Not established

Key unknowns

Program-level outcomes outside this reviewed profile remain unknown; absence is not a negative finding.
The reviewed evidence does not resolve this dimension beyond the recorded boundary.

Next evidence milestone

What would change this view?

No specific evidence milestone is recorded yet.

Evidence reviewed through 2026-08-07.

Intelligence connections

Develops or sponsors

Nicotinamide riboside

Intervention

Nicotinamide riboside in obese insulin-resistant men

Trial

Reviewed source layer

Evidence & sources

These cards show only metadata present in the reviewed source registry.

trial registry

Nicotinamide Riboside in Obese Men

ClinicalTrials.gov

Reference: NCT02303483

Reviewed: 2026-08-06

bibliographic index

Nicotinamide riboside does not alter mitochondrial respiration in obese insulin-resistant men

PubMed

Reference: 31710095